IPD: ImpediMed Limited - Summary | Jitta

ImpediMed Limited

AUS:IPD

Price
AU$0.01
Loss Chance
50.8%
3.30JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
39 / 126
429 / 1,069
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (47)
Recent Business Performance (44)
Financial Strength (29)
Return to Shareholders (0)
Competitive Advantage (52)
Jitta Signs
SG&A to SalesDecreasing
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2025
CapExVery High
Key Stats
Jitta Score
Jitta Line
3.30
100.00%
2.66
154.92%
Health Care Equipment
4.82
568.56%
6.55
35.22%
3.26
100.00%
COMPANY DESCRIPTION
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California with additional office in Lindfield, Australia.